Jul 26 |
Leqembi voted down by European regulators
|
Jul 26 |
Biogen-partnered Alzheimer’s therapy fails to clear EU hurdle
|
Jul 26 |
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
|
Jul 25 |
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
|
Jul 25 |
Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial
|
Jul 24 |
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
|
Jul 24 |
Sage Therapeutics Collapses 19% After Biogen-Tied Essential Tremor Drug Fails
|
Jul 24 |
Sage Therapeutics Stock Slides as Pipeline Thins
|
Jul 24 |
Is Biogen (BIIB) an Underappreciated Stock?
|
Jul 24 |
Biogen, Sage tremor drug fails key trial
|